PARP inhibitors and prostate cancer: A new era of precision medicine
PARP inhibitors and prostate cancer: A new era of precision medicine
Atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers
New strategy for ecancermedicalscience: supporting publications in under-resourced settings
CaRE2 Cancer Research Link© : Introducing the CaRE2 Health Equity Center
Oncology pharmacist perspective on PARP inhibitors for castration-resistant prostate cancer
The role of PARP-2 in inhibiting prostate cancer
OncoAlert and ecancer weekly roundup for July 19-25 2020
Epidemiology of gastric cancer
Prophylactic mastectomy and breast surveillance
Laboratory analysis of CDH1 missense mutation
The European Cancer Prevention Organization
Future perspective of CDH1 mutation in gastric and breast cancers